147 related articles for article (PubMed ID: 10382096)
1. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X
Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096
[TBL] [Abstract][Full Text] [Related]
2. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
3. Indium-111-pentetreotide in Graves' disease.
Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
[TBL] [Abstract][Full Text] [Related]
4. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.
Moncayo R; Baldissera I; Decristoforo C; Kendler D; Donnemiller E
Thyroid; 1997 Feb; 7(1):21-9. PubMed ID: 9086565
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
7. 111In-octreotide imaging in patients with long-standing Graves' ophthalmopathy.
Bohuslavizki KH; Oberwöhrmann S; Brenner W; Eberhardt JU; Mönig H; Clausen M; Sippel C; Wolf H; Epe B; Henze E
Nucl Med Commun; 1995 Nov; 16(11):912-6. PubMed ID: 8587756
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity.
Förster GJ; Krummenauer F; Nickel O; Kahaly GJ
Cancer Biother Radiopharm; 2000 Oct; 15(5):517-25. PubMed ID: 11155823
[TBL] [Abstract][Full Text] [Related]
9. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptors in the orbits.
Durak I; Durak H; Ergin M; Yürekli Y; Kaynak S
Clin Nucl Med; 1995 Mar; 20(3):237-42. PubMed ID: 7750218
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging in patients with sarcoidosis.
Kwekkeboom DJ; Krenning EP; Kho GS; Breeman WA; Van Hagen PM
Eur J Nucl Med; 1998 Sep; 25(9):1284-92. PubMed ID: 9724378
[TBL] [Abstract][Full Text] [Related]
13. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.
Gerding MN; van der Zant FM; van Royen EA; Koornneef L; Krenning EP; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 1999 Mar; 50(3):373-9. PubMed ID: 10435064
[TBL] [Abstract][Full Text] [Related]
14. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
[TBL] [Abstract][Full Text] [Related]
15. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
16. Octreoscan in thyroid-associated ophthalmopathy.
Krassas GE
Thyroid; 2002 Mar; 12(3):229-31. PubMed ID: 11952044
[TBL] [Abstract][Full Text] [Related]
17. 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy.
Yüksel M; Eziddin S; Wardelmann E; Biersack HJ
Rev Esp Med Nucl; 2006 Sep; 25(5):316-9. PubMed ID: 17173778
[TBL] [Abstract][Full Text] [Related]
18. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease.
Colao A; Pivonello R; Lastoria S; Faggiano A; Ferone D; Lombardi G; Fenzi G
Eur J Endocrinol; 2000 Oct; 143 Suppl 1():S35-42. PubMed ID: 11068938
[No Abstract] [Full Text] [Related]
20. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
